

Huei Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9062468/publications.pdf>

Version: 2024-02-01

48
papers

4,007
citations

201674

27
h-index

189892

50
g-index

50
all docs

50
docs citations

50
times ranked

6111
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2005, 97, 339-346.	6.3	2,194
2	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0142656.	2.5	176
3	Paxillin Predicts Survival and Relapse in Non-“Small Cell Lung Cancer by MicroRNA-218 Targeting. <i>Cancer Research</i> , 2010, 70, 10392-10401.	0.9	121
4	Human Papillomavirus 16/18 E6 Oncoprotein Is Expressed in Lung Cancer and Related with p53 Inactivation. <i>Cancer Research</i> , 2007, 67, 10686-10693.	0.9	115
5	Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. <i>Oncotarget</i> , 2015, 6, 41692-41705.	1.8	105
6	Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway Is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus-Associated Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1895-1905.	7.0	83
7	Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries. <i>Scientific Reports</i> , 2017, 7, 40003.	3.3	68
8	cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5200-5210.	7.0	67
9	IL-10 Promotes Tumor Aggressiveness via Upregulation of CIP2A Transcription in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4092-4103.	7.0	59
10	A Polymorphic 844T/C in <i>FasL</i> Promoter Predicts Survival and Relapse in Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5991-5999.	7.0	55
11	Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. <i>Carcinogenesis</i> , 2014, 35, 1823-1829.	2.8	53
12	Loss of TIMP-3 Promotes Tumor Invasion via Elevated IL-6 Production and Predicts Poor Survival and Relapse in HPV-Infected Non-“Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1796-1806.	3.8	49
13	MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of β -catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer. <i>Carcinogenesis</i> , 2014, 35, 2175-2182.	2.8	46
14	Up-Regulation of FOXM1 by E6 Oncoprotein through the MZF1/NKX2-1 Axis Is Required for Human Papillomavirus-Associated Tumorigenesis. <i>Neoplasia</i> , 2014, 16, 961-971.	5.3	44
15	The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in <i>KRAS</i> -wild-type colorectal cancer. <i>Theranostics</i> , 2017, 7, 1114-1132.	10.0	43
16	PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression. <i>Oncotarget</i> , 2018, 9, 4637-4646.	1.8	43
17	DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β -catenin/ZEB1 axis. <i>Oncotarget</i> , 2016, 7, 22687-22699.	1.8	40
18	MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc. <i>Annals of Surgical Oncology</i> , 2015, 22, 1532-1539.	1.5	39

#	ARTICLE	IF	CITATIONS
19	PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation. <i>Clinical Cancer Research</i> , 2016, 22, 5370-5382.	7.0	39
20	Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2. <i>Oncotarget</i> , 2016, 7, 32362-32374.	1.8	38
21	MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF- κ B/Snail/Bcl-2 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 79, 127-137.	2.9	36
22	Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression. <i>Toxicology Letters</i> , 2015, 237, 46-54.	0.8	35
23	A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. <i>Theranostics</i> , 2018, 8, 1256-1269.	10.0	34
24	DDX3 promotes tumor invasion in colorectal cancer via the CK1 μ /Dvl2 axis. <i>Scientific Reports</i> , 2016, 6, 21483.	3.3	33
25	Human Telomerase Reverse Transcriptase Activated by E6 Oncoprotein Is Required for Human Papillomavirus-16/18-Infected Lung Tumorigenesis. <i>Clinical Cancer Research</i> , 2008, 14, 7173-7179.	7.0	32
26	Cytoplasmic localization of Nrf2 promotes colorectal cancer with more aggressive tumors via upregulation of PSMD4. <i>Free Radical Biology and Medicine</i> , 2016, 95, 121-132.	2.9	32
27	PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells. <i>Oncology Reports</i> , 2017, 38, 1115-1123.	2.6	32
28	PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β -catenin-mediated stemness. <i>Scientific Reports</i> , 2016, 6, 34933.	3.3	27
29	An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. <i>European Journal of Cancer</i> , 2017, 85, 95-105.	2.8	26
30	Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression. <i>International Journal of Biological Sciences</i> , 2018, 14, 47-56.	6.4	25
31	MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. <i>Oncotarget</i> , 2018, 9, 13758-13767.	1.8	24
32	Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87. <i>Oncotarget</i> , 2015, 6, 8698-8708.	1.8	23
33	A combination of anti-PD-L1 antibody plus LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers. <i>Cancer Medicine</i> , 2017, 6, 2052-2062.	2.8	21
34	Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer. <i>Pathology Research and Practice</i> , 2019, 215, 801-806.	2.3	18
35	Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 3367-3376.	4.1	17
36	PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2. <i>Oncotarget</i> , 2018, 9, 26342-26352.	1.8	15

#	ARTICLE	IF	CITATIONS
37	NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKK ^{Î²} /NF-Î²B activation. <i>Oncotarget</i> , 2015, 6, 14274-14289.	1.8	15
38	The APE1 Asp/Asp Genotype and the Combination of APE1 Asp/Asp and hOGG1-Cys Variants Are Associated With Increased p53 Mutation in Non-Small Cell Lung Cancer. <i>Journal of Epidemiology</i> , 2012, 22, 537-542.	2.4	13
39	Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769431.	1.8	12
40	MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer. <i>Surgery</i> , 2016, 160, 1591-1598.	1.9	9
41	Hepatitis B virus X protein represses LKB1 expression to promote tumor progression and poor postoperative outcome in hepatocellular carcinoma. <i>Surgery</i> , 2018, 163, 1040-1046.	1.9	9
42	Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 4017-4023.	1.8	8
43	Cytoplasmic p27 ^{Kip1} promotes tumorigenesis via suppression of RhoB activity. <i>Journal of Pathology</i> , 2019, 247, 60-71.	4.5	8
44	Novel function of PERP-428 variants impacts lung cancer risk through the differential regulation of PTEN/MDM2/p53-mediated antioxidant activity. <i>Free Radical Biology and Medicine</i> , 2021, 167, 307-320.	2.9	7
45	Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1904-1910.	1.9	6
46	PD-L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGFÎ²1/SMAD4 expression. <i>Thoracic Cancer</i> , 2022, 13, 1322-1332.	1.9	5
47	Association of hOGG1 Cys variants with occurrence of p53 and EGFR deletion mutations in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 534-538.	1.9	3
48	A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine to suppress tumor growth and metastasis in HPV-infected cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, e23175-e23175.	1.6	1